AI & Machine Learning

同乐城TLC官网 www.zhaoxuefen.com  

 

Debating the limitless applications of artificial intelligence, quantum and bioinformatics into clinical decision support, predictive diagnostics, drug discovery and development, data scalability, text mining, and image recognition.

 

AI & Machine Learning, Thursday 10 October 2019

08:00

Registration & Breakfast

Plenary Keynotes

Ed Simcox
08:40

Data innovation in the American government: how the HHS effectively leverages data, technology and innovation to improve lives

Gianluca Pettiti
09:00

Automating data: how AI and automation will impact the use of data applied to lab interconnectivity and sample analysis

Arpa Garay
09:20

C-level / SVP Pharma Panel

Data strategies for R&D, addressing the importance of privacy, leveraging new technology and analytics for product commercialization, and integrating data into pharma companies.
10:20

Networking Coffee Break

Data Scalability

Christina Silcox
AI & Machine Learning
11:00

Software as a medical device: approaching challenges to the adoption and regulation of AI-enabled software and improving the quality of real world data

Prasun Mishra
AI & Machine Learning
11:20

The convergence of big data and AI: how big data enables artificial intelligence to provide more meaningful results and how to apply that learning to your company

James Dzierzanowski
AI & Machine Learning
11:40

Quantum privacy computing at scale: how quantum computing can be more secure than traditional RSA computing and its potential to secure data at scale

More information soon.
12:20

Networking Lunch

ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30 minutes – attendees can select two roundtables to attend)

13:40

Roundtable: AI integration: how incorporating AI into all phases of drug development from target discovery, to the recovery of failed projects is transforming pharma

Jill Bonjean
13:40

Roundtable: Cross-sector networking for rare diseases: exploring vital data from AI, devices, research, and IT related to rare disease patients

Jill Bonjean, Corporate Relations Advisor, Rare Disease International
Pamela Mace, President, Fibromuscular Dysplasia Society of America
Stephen Groft
13:40

Roundtable: Diversity in clinical research: how to use data to increase ethnic, racial, and gender diversity in clinical trials to improve outcomes for patients of all backgrounds

Stephen Groft, Senior Advisor To The Director, Ncats, NIH
Monika Schneider
13:40

Roundtable: Incentivizing orphan drug innovation: how to motivate companies to develop orphan drugs through changes to reimbursement and tax incentives

Stephan Schuster
13:40

Roundtable: Microbiomes as indicators of health: how the surrounding environment can impact human health, and an examination of the data supporting this as evidence

Fergal Mccaffery
13:40

Roundtable: Mitigating the risk of mobile healthcare

How to secure data with the influx of healthcare apps and the move to patient interaction via mobile devices by conducting more frequent HIPAA security checks and penetration-testing / vulnerability-assessments of IT systems.
Yizhen Dong
13:40

Roundtable: Multidisciplinary approaches: how to apply digital data to drug discovery, use new technology for data mining, and utilize machine learning

Jenny Royle
13:40

Roundtable: The impact of safety data collection: how to treat disease and improve the quality of life for patients while properly characterizing the effects of the drug

Eric Weintraub
13:40

Roundtable: Using data to develop innovative telemedicine programs: sharing ideas for the creation and implementation of telehealth programs

Drug Discovery & Development

Olexandr Isayev
AI & Machine Learning
14:50

Using artificial intelligence to design new molecules: how to use a novel computational strategy knows as Reinforcement Learning for Structural Evolution to employ data for the design of new molecules

Govinda Bhisetti
AI & Machine Learning
15:10

In silico drug design: how to use computer simulations to identify/validate target biomarkers, discover/optimize leads, and perform pre-clinical tests

Adam Godzik
AI & Machine Learning
15:30

Prioritizing targets: how to lower the cost and time needed for drug discovery by incorporating AI to assess the level of confidence of a target and choose a druggable protein

Networking Coffee Break

Plenary Keynotes

Data Democratization

17:30

Closing remarks followed by networking drinks reception

More information soon.
last published: 23/Aug/19 20:05

AI & Machine Learning, Friday 11 October 2019

08:00

Registration & Breakfast

Plenary Keynotes

Debbie Profit
09:00

Collaboration for innovation: a case study discussion about Project Baseline’s digitally innovative, patient-centered approach to challenges with data fragmentation within research programs

10:20

Networking coffee break

Text Mining & Image Recognition

Faisal Khan
AI & Machine Learning
11:00

Analyzing multiple information modalities: how to combine imaging data, text mining, devices

More information soon.
Mark Punyanitya
AI & Machine Learning
11:20

Imaging data: how personalized imaging can benefit population health by improving monitoring and lowering overall cost

Lina Nilsson
AI & Machine Learning
11:40

Transforming drug discovery: how AI and image data sets helps understanding how healthy cells are impacted by diseases and consequently guide therapy development

12:20

Networking Lunch

June Lee
13:40

Roundtable: AI for therapeutics: how to apply automation and machine learning to treatments and encourage the use of AI beyond drug discovery

Amelia Anderson
13:40

Roundtable: Computational molecular dynamics: small molecule data approaches for modifying drugs and identifying targets

Manuel Corpas
13:40

Roundtable: Genomic interpretation for accurate diagnoses: how to simplify the process of genetic screening from sample to report interpretation

Nadeem Sarwar
13:40

Roundtable: Genomics in drug discovery: how to expedite the drug development through genomics and structural/cultural changes

Eve Bukowski
13:40

Roundtable: Strategic data presentations for government support

How to engage government officials by shifting from the use of quantitative data (hard numbers) to qualitative data (telling the patient story) in your presentation.
Hollie Schmidt

ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30 minutes – attendees can select two roundtables to attend)

15:30

End of Conference

last published: 23/Aug/19 20:05

 

Contact us

To sponsor or exhibit contact:
André Singer
t/ 646.619.1797 

andre.singer@www.zhaoxuefen.com


To speak:
Anna Bagley
t/ 646 619-1803 

anna.bagley@www.zhaoxuefen.com